Ketamine and Psilocybin Update in Treatment-Resistant Depression
Studies from Psych Congress 2022 show the efficacy of ketamine and psilocybin in reducing symptoms of treatment-resistant depression.
Studies from Psych Congress 2022 show the efficacy of ketamine and psilocybin in reducing symptoms of treatment-resistant depression.
How does consumption of processed food by children with atopy and asthma affect the gut microbiota and disease severity?
To what extent are patients with uncontrolled asthma switched to biologics due to poor treatment adherence vs lack of maintenance therapy efficacy?
How does a short-term halt in peanut oral immunotherapy or a reduced dosing frequency affect children who have already received a year of peanut OIT?
What dosage of dexamethasone most effectively improves outcomes in patients hospitalized with moderate or severe COVID-19 pneumonia?